Private Equity

Updated:

Regal Healthcare Capital Partners

Regal Healthcare Capital Partners is a private equity investment firm investing in lower and middle market companies in the healthcare service sector.

Regal Healthcare Capital Partners logo

Regal Healthcare Capital Partners

Regal Healthcare Capital Partners is a private equity investment firm investing in lower and middle market companies in the healthcare service sector.

General information

Firm type

Private Equity

Year founded

2018

AUM

Undisclosed

Location

Region

North America

Country

United States

City

New York

Corporate office

One Penn Plaza, Suite 4610, New York, NY 10119, United States

Principals

David Kim

Co-Founder and General Partner

Jon Santemma

Co-Founder and General Partner

Sector focus

Healthcare Services

Frequently asked questions

Who runs investment decisions at Regal Healthcare Capital Partners?

Investment decisions are made by Co-Founders and General Partners Dr. David Kim and Jon Santemma. Kim is a board-certified emergency physician and serial healthcare entrepreneur who co-founded CityMD, Dental365, and Progressive Emergency Physicians; Santemma was Global Head of Healthcare Investment Banking at Jefferies from 2009 to 2018 and previously ran healthcare services coverage at UBS.

How does Regal source proprietary deal flow?

Regal's sourcing model leans on the clinical and entrepreneurial networks of its physician-operator co-founder. With three prior exits as a founder and an active role on the attending staff at Northwell Health, Kim accesses a pipeline of physician-led, multi-site businesses that sit below the radar of larger healthcare private equity platforms.

Is Regal structured as a single family office or does it operate more like a venture firm?

Regal operates as a private equity asset manager, not a family office. It deploys institutional capital through a control growth equity and buyout mandate and does not identify a single-family wealth source.

Does Regal participate in fund commitments or only direct deals?

The firm's public materials describe direct control growth equity and buyout investments. No information on fund-of-fund commitments or LP allocations to external managers has been disclosed.

What investment stages does Regal typically target?

Regal targets control growth equity and buyout investments in the smaller end of the lower middle market, typically backing multi-site and provider-led healthcare services companies with $20–100 million in revenue and $2–10 million in EBITDA, writing equity checks of $30–70 million.

Which sectors does Regal explicitly avoid?

Regal concentrates exclusively on healthcare services and has not disclosed investments outside that vertical. The website identifies no exposure to medical devices, biopharma, health-tech SaaS, or non-healthcare sectors.

Does Regal maintain philanthropic structures, and how are they separated?

No separate philanthropic foundation is disclosed in the firm's public materials or team biographies.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More New York Private Equity profiles